Public notice

The therapeutic efficacy results of a candidate immunomodulatory imide drug developed under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, ACS P

관리자 │ 2023-10-13

HIT

158

The therapeutic efficacy results of a candidate immunomodulatory imide drug developed under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, ACS Pharmacology & Translational Science (March 30, 2021).

 

 

The study, titled, N-Adamantyl Phthalimidine: A New Thalidomide-like Drug That Lacks Cereblon Binding and Mitigates Neuronal and Synaptic Loss, Neuroinflammation, and Behavioral Deficits in Traumatic Brain Injury and LPS Challenge may be found here (https://doi.org/10.1021/acsptsci.1c00042).

 

이전글 Research on the immunomodulatory imide drugs development under the Cooperative R...
다음글 Researches on immunomodulatory imides drug development under the Cooperative Res...